Bristol puts Mirati out of its misery
The acquisition brings closure for Mirati at last, though some investors will feel disappointed.
Lumakras withdrawal seems unlikely... for now
But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.
Bridge mirrors Black Diamond and Blueprint’s search for something better
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
Moderna moves on swiftly with its neoantigen immunotherapy
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.
World Lung 2023 – Flaura2 leaves a gap open for J&J
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
